ADMA Biologics, Inc.

ADMA Biologics, Inc.

ADMANYSE / NASDAQHealthcareMid cap

$13.17-$0.17 (-1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
12.6x
EV / EBITDA
9.3x
Revenue
$510.2M
Net margin
28.8%
ROCE
34.5%

-19.5% over the last year

ADMA Biologics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+17.3%
3M
+34.9%
6M
+53.9%
1Y
-19.5%
5Y
+760.8%

52-week range

Day change -$0.17 (-1.3%) from $13 to $13 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ADMA, bought on each weekday since 2021.

News & filings

What ADMA Biologics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 37.5% against a peer median of 10.1%.

Concerns (1)

  • Operating cash flow was 0.34 times net profit in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Read moreShow less

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector
Healthcare
Shares outstanding
237.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
12.6x
P/B
3.9x
EV / EBITDA
9.3x
EV / Sales
3.6x
P/S
3.6x
52-week high
$20.38
52-week low
$7.60

Profitability

Operating margin
37.5%
Net margin
28.8%
EBITDA margin
38.8%
ROE
30.8%
ROCE
34.5%
ROA
23.5%
Asset turnover
0.82

Growth

Revenue
$510.2M
Revenue growth, 1Y
19.6%
Revenue CAGR, 3Y
49.0%
Net profit growth, 1Y
-25.7%
Free cash flow
$27.5M

Solvency

Current ratio
6.71
Debt / Equity
0.17
Debt / Assets
0.13
CFO / Net profit
0.34
Cash / Market cap
4.7%

Where the revenue went

Of every $100 of FY2025 revenue, $29 was left as net income.

ADMA Biologics, Inc. income statement flow, FY2025
ADMA Biologics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$217.4M
RevenueGross profit$292.8M
Gross profitResearch and development$4.8M
Gross profitSelling, general and administrative$91.6M
Gross profitOther operating expenses$5.0M
Gross profitOperating income$191.4M
Operating incomePretax income$182.7M
Operating incomeInterest and other expense$8.8M
Pretax incomeTax and other$35.7M
Pretax incomeNet income$146.9M

Revenue and net profit

Revenue grew 19.6% in FY2025; net profit is the dashed line.

ADMA Biologics, Inc. revenue and net profit by fiscal year
ADMA Biologics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$154.1M-$65.9M
FY2023$258.2M-$28.2M
FY2024$426.5M$197.7M
FY2025$510.2M$146.9M

Cash flows

FY2025: $50.4M from operations, $27.5M free after investment (dashed).

ADMA Biologics, Inc. operating and free cash flow by fiscal year
ADMA Biologics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$59.5M-$73.4M
FY2023$8.8M$3.8M
FY2024$118.7M$110.1M
FY2025$50.4M$27.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$510.2M+19.6%1Y
EBITDA
$197.9M+34.0%1Y
Net profit
$146.9M-25.7%1Y
Cash from operations
$50.4M-57.5%1Y
Free cash flow
$27.5M-75.0%1Y
Revenue CAGR, 3Y
49.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$510.2M$197.9M$146.9M$27.5M30.8%+19.6%-25.7%

Monthly returns

Month-by-month returns of ADMA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$624.2M
Liabilities$146.9M
Equity$477.3M
Paid-in capital$671.0M
Retained earnings-$161.7M
Treasury stock$32.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ADMA highlighted.

P/E against peers

ADMA trades at 12.6x earnings against a peer median of 12.1x.

Not shown (no positive earnings and no EV / Sales): Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ADMA Biologics, Inc.ADMAthis company$1.8B12.6x3.9x30.8%9.3x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
Sarepta Therapeutics, Inc.SRPT$1.8B-2.5x1.5x-62.5%-3.2x
Phibro Animal Health CorporationPAHC$1.3B27.8x4.7x16.9%13.8x
Peer median—12.1x1.4x9.3%9.3x

Year-to-date ROI

ADMA since 1 January, against earlier years.

Historical volatility

ADMA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ADMA Biologics, Inc. operating margin by fiscal year
ADMA Biologics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-25.5%
FY20238.4%
FY202432.6%
FY202537.5%
LineFY2025
Cost of revenueCost Of Revenue$217.4M
Gross profitGross Profit$292.8M
Operating expensesOperating Expense$101.3M
Research and developmentResearch And Development$4.8M
Selling, general and administrativeSelling General And Administration$91.6M
Other operating expensesOther Operating Expenses$4.8M
Depreciation and amortisationDepreciation And Amortization In Income Statement$140.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$140.0k
Amortization$140.0k
Amortisation of intangiblesAmortization Of Intangibles Income Statement$140.0k
Total expensesTotal Expenses$318.7M
Pretax incomePretax Income$182.7M

Learn while you research

Academy chapters picked for ADMA Biologics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →